AmbioPharm, Inc.

AmbioPharm, which has manufacturing sites in US and China, provides small-scale (ie, milligrams) non-GMP and cGMP-compliant peptide manufacturing as well as mid- to large-scale (ie, ton per year) cGMP-compliant peptide manufacturing services. AmbioPharm uses solid phase and liquid phase synthesis methods, the combination of these two (i.e., hybrid method), and microwave-based method for the chemical synthesis of peptides with up to 70-80 amino acids. In addition, AmbioPharm provides peptide formulation development services as well.